Life Sciences

  • July 27, 2026

    AbbVie Seeks Block On Alkem Generic Constipation Drug

    AbbVie Inc. and collaborator Ironwood Pharmaceuticals urged a New Jersey federal court to bar India-based generic-drug maker Alkem Laboratories from selling generic versions of their branded constipation drug while associated patents are active, arguing Alkem would violate patent law by doing so.

  • July 27, 2026

    Regeneron Says Drug Approval Irrelevant In Antitrust Case

    Regeneron told a Delaware federal court the recent regulatory approval of a new cholesterol drug is irrelevant to its case accusing Amgen of bundling Repatha with other medications, as the court mulls an injunction bid following Regeneron's $407 million jury win.

  • July 27, 2026

    Hemp Co. Says DEA Defied Farm Bill By Banning HHC

    A North Carolina hemp company challenging the legality of a recent U.S. Drug Enforcement Administration rule designating a psychoactive hemp-derived compound as a Schedule I substance has told the Fourth Circuit that the agency defied Congress when it issued the rule.

  • July 27, 2026

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court last week tackled disputes involving restrictive covenants, corporate governance, trade secrets, real estate investments, receiverships, and books and records demands.

  • July 27, 2026

    Stewart Leaving USPTO This Week For Private Sector Job

    Deputy U.S. Patent and Trademark Office Director Coke Morgan Stewart will leave the office this week to return to the private sector, she told the USPTO executive staff Monday in a message obtained by Law360.

  • July 27, 2026

    Cannabis In The Courts: A Midyear Litigation Review

    In the first half of 2026, lawsuits taking aim at recent federal shifts in cannabis policy, a federal ban on marijuana users owning firearms and purported residency criteria in state cannabis licensure programs were argued in multiple courts across the country.

  • July 27, 2026

    Alkegen Files Ch. 11 In Texas To Shed $3.1B In Debt

    Alkegen and dozens of affiliates filed a prepackaged Chapter 11 case in Texas bankruptcy court, where the specialty materials maker intends to cut the bulk of its $3.3 billion of funded debt obligations.

  • July 27, 2026

    Arnold & Porter Hires King & Spalding ITC-Focused Atty

    Arnold & Porter Kaye Scholer LLP has hired a King & Spalding LLP partner in Washington, D.C., who will continue his intellectual property work focused on the cross-border aspects of technology and life sciences disputes, the firm announced Monday.

  • July 27, 2026

    Commerce Orders Duties On Korean Chemical Imports

    Certain monomers and oligomers imported into the U.S. from South Korea will be tagged with antidumping duties following an order by the U.S. Department of Commerce on Monday.

  • July 24, 2026

    Abbott Beats 'Supersized' Investor Suit Over Formula Recall

    An Illinois federal judge tossed a proposed securities class action accusing Abbott Laboratories of misleading shareholders about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, saying Friday that "despite its girth," the "supersized" complaint says "too much and too little," and still needs more information to be viable.

  • July 24, 2026

    Abbott Wins 7th Circ. Fight Over Baby Formula Warning

    The Seventh Circuit on Friday refused to revive a woman's claims that Abbott Laboratories failed to warn about the dangers of a Similac-brand infant formula her baby drank before dying of a serious gastrointestinal disease, saying she failed to show that her suggested alternative warning would have saved her baby.

  • July 24, 2026

    Va. Court Orders FDA To Reconsider Mifepristone Restrictions

    A Virginia federal judge held that a 2023 regulation by the U.S. Food and Drug Administration unlawfully placed prescribing restrictions on the abortion drug mifepristone, agreeing with a group of abortion providers that the agency inadequately addressed burdens on the healthcare system.

  • July 24, 2026

    Insulin Pen Lawsuit Against Novo Nordisk Headed For Trial

    A Connecticut federal judge refused on Friday to give Griffin Health Services Corp. a loss in its lawsuit over allegedly inadequate warnings on Novo Nordisk insulin pens, finding the hospital raised triable questions about whether the company failed to alert nurses to contamination risks and criticizing Novo for filing multiple summary judgment motions.

  • July 24, 2026

    9th Circ. Revives Ex-Kaiser Worker's Vaccine Bias Suit

    A Ninth Circuit panel Friday revived a former Kaiser Permanente employee's discrimination suit accusing The Permanente Medical Group Inc. of unlawfully firing her for refusing a mandatory COVID-19 vaccine, ruling that the worker adequately informed the company of the vaccine's conflict with her sincerely held religious beliefs.

  • July 24, 2026

    Full Fed. Circ. Urged To Reconsider Pfizer's Paxlovid IP Win

    Enanta Pharmaceuticals is asking the Federal Circuit to rethink its June refusal to revive a patent it had asserted against Pfizer over its COVID-19 treatment Paxlovid, saying the court acted beyond its authority.

  • July 24, 2026

    'Irreparable': The Lasting Harm Of Justices' Temporary Orders

    The U.S. Supreme Court has considered dozens of emergency petitions involving executive policies since President Donald Trump's return to office. While justices often defend their emergency rulings as stop-gap measures, people at the center of those cases — who've lost their legal status, jobs, or federal funding — say that even interim decisions have had lasting effects on their lives.

  • July 24, 2026

    Pet Medical Co. Sheds Dog Arthritis Drug Suit For Good

    A New Jersey federal judge has thrown out for good a proposed nationwide class action alleging Zoetis Inc. hid the dangerous side effects of its canine osteoarthritis drug, finding the complaint failed to plead the plaintiffs relied on any misrepresentations to their dogs' detriment.

  • July 24, 2026

    Finch Therapeutics Can Seek Ch. 11 Plan Votes

    A Delaware bankruptcy judge on Friday conditionally approved the disclosure statement for microbiome treatment developer Finch Therapeutics' Chapter 11 plan, allowing it to solicit creditor votes.

  • July 24, 2026

    Novo Asks NJ Judge To Stop Lilly's 'Deceptive' GLP-1 Ads

    Novo Nordisk Inc. asked a New Jersey federal court Friday to block rival Eli Lilly & Co. from running ads allegedly comparing their respective GLP-1 drugs using "outdated" clinical trials and "false superiority messages," arguing the ads are damaging its reputation and misleading consumers.

  • July 24, 2026

    Fenwick, Latham Lead Scribe Therapeutics' $129M IPO

    Early-stage biotechnology firm Scribe Therapeutics began trading publicly on Friday after raising $129 million in its upsized initial public offering steered by Fenwick & West LLP and Latham & Watkins LLP.

  • July 24, 2026

    Top Product Liability Cases Of 2026: Midyear Report

    In one of the most-watched cases for product liability so far this year, the U.S. Supreme Court ruled that failure-to-warn claims about the alleged cancer risks of Monsanto's widely used pesticide Roundup are barred by federal law. Social media titans were also rocked by the first verdicts delivered in cases alleging mental health harms to youth.

  • July 24, 2026

    CVS Seeks Toss Of Hospitals' 340B Suits In NY, Mich.

    CVS urged New York and Michigan federal courts to toss separate suits brought by hospital operators accusing the health giant of diverting savings from the federal 340B Drug Pricing Program to itself, saying the suits purport to raise key questions about the program when they actually concern simple contract disputes.

  • July 24, 2026

    Former Drug Co. Akorn Gets OK For $18.5M Ch. 7 Settlement

    A Delaware bankruptcy judge has signed off on a deal resolving a $28.3 million claim by the buyer of defunct drug developer Akorn's assets, allowing an $18.5 million claim in the Chapter 7 case.

  • July 23, 2026

    Texas Panel Overturns Abortion Injunction Against Midwife

    A Texas appellate court overturned a temporary injunction against a licensed Houston-area midwife accused by state prosecutors of violating Texas' abortion ban, finding Thursday a trial court wrongly admitted probable-cause affidavits from a related criminal case.

  • July 23, 2026

    AstraZeneca Immune In Vax Trial Contract Suit, 10th Circ. Says

    The Tenth Circuit on Thursday overturned a lower court ruling that AstraZeneca lacked immunity from an experimental COVID-19 vaccine trial participant's lawsuit seeking medical compensation after she suffered debilitating injuries, saying a federal statute providing immunity for vaccine developers covers her contract breach claims.

Expert Analysis

  • Record FCA Recoveries Signal Intensified Healthcare Focus

    Author Photo

    In its recently released False Claims Act statistics, the U.S. government's emphasis on record healthcare recoveries and government-initiated healthcare matters last year indicates robust enforcement ahead, though the administration's focus on current policy objectives also extends beyond the healthcare sector, say attorneys at Epstein Becker.

  • Fed. Circ. In Jan.: On The Validity Of Expert Testimony

    Author Photo

    The Federal Circuit's recent decision in Barry v. DePuy, addressing whether expert testimony is admissible even if it does not strictly adhere to the court's claim construction, suggests that exclusion via a Daubert motion is appropriate only when the line to improper testimony is clearly crossed, say attorneys at Knobbe Martens.

  • Calif.'s Civility Push Shows Why Professionalism Is Vital

    Author Photo

    The California Bar’s campaign against discourteous behavior by attorneys, including a newly required annual civility oath, reflects a growing concern among states that professionalism in law needs shoring up — and recognizes that maintaining composure even when stressed is key to both succeeding professionally and maintaining faith in the legal system, says Lucy Wang at Hinshaw.

  • A Potential Shift In FDA's Approach To Drug Trial Design

    Author Photo

    Recent guidance released by the U.S. Food and Drug Administration clarifying how Bayesian approaches — which combine prior knowledge with new data — may be used in clinical trials reflects the agency's continued interest in innovative trial designs that may accelerate drug approvals, say attorneys at Alston & Bird.

  • Series

    Trivia Competition Makes Me A Better Lawyer

    Author Photo

    Playing trivia taught me to quickly absorb information and recognize when I've learned what I'm expected to know, training me in the crucial skills needed to be a good attorney, and reminding me to be gracious in defeat, says Jonah Knobler at Patterson Belknap.

  • What FDA Guidance Means For Future Of Health Software

    Author Photo

    Two significant final guidance documents released by the U.S. Food and Drug Administration last month reflect a targeted effort to ease innovation friction around specific areas, including singular clinical decision support recommendations and sensor-based wearables, while maintaining established regulatory boundaries, say attorneys at Covington.

  • Opinion

    Federal Preemption In AI And Robotics Is Essential

    Author Photo

    Federal preemption offers a unified front at a decisive moment that is essential for safeguarding America's economic edge in artificial intelligence and robotics against global rivals, harnessing trillions of dollars in potential, securing high-skilled jobs through human augmentation, and defending technological sovereignty, says Steven Weisburd at Shook Hardy.

  • Series

    Law School's Missed Lessons: What Cross-Selling Truly Takes

    Author Photo

    Early-career attorneys may struggle to introduce clients to practitioners in other specialties, but cross-selling becomes easier once they know why it’s vital to their first years of practice, which mistakes to avoid and how to anticipate clients' needs, say attorneys at Moses & Singer.

  • Drafting Tech Patents After USPTO's Eligibility Memos

    Author Photo

    Two recent U.S. Patent and Trademark Office memos on subject matter eligibility declarations provide an evidentiary playbook for artificial intelligence and software patent applications, highlighting how targeted, stand‑alone SMEDs that present objective, claim‑anchored facts can improve patent application outcomes, say attorneys at Reed Smith.

  • How State FCA Activity May Affect Civil Fraud Enforcement

    Author Photo

    A growing trend of state attorneys general enforcing their False Claims Act analogues independently of the U.S. Department of Justice carries potential repercussions for civil fraud enforcement and qui tam litigation considerations, say Li Yu at Bernstein Litowitz, Ellen London at London & Naor and Gwen Stamper at Vogel Slade.

  • Series

    Judges On AI: Practical Use Cases In Chambers

    Author Photo

    U.S. Magistrate Judge Allison Goddard in the Southern District of California discusses how she uses generative artificial intelligence tools in chambers to make work more efficient and effective — from editing jury instructions for clarity to summarizing key documents.

  • Assessing Compliance Risks Around TrumpRx Participation

    Author Photo

    As there are novel compliance obligations and potential political opposition related to the new TrumpRx online drug platform, companies intending to participate on the site should consider the pressure points that are likely to draw enforcement scrutiny, say attorneys at Sheppard.

  • USPTO Initiatives May Bolster SEP Litigation In The US

    Author Photo

    The U.S. Patent and Trademark Office's recent efforts to revitalize standard-essential patent litigation face hurdles in their reliance on courts and other agencies, but may help the U.S. regain its central role in global SEP litigation if successful, say attorneys at Axinn.

  • Series

    Trail Running Makes Me A Better Lawyer

    Author Photo

    Navigating the muddy, root-filled path of trail marathons and ultramarathons provides fertile training ground for my high-stakes fractional general counsel work, teaching me to slow down my mind when the terrain shifts, sharpen my focus and trust my training, says Eric Proos at Next Era Legal.

  • Predicting Actual Impact From CDC's New Vaccine Guidance

    Author Photo

    Recent federal changes to the childhood immunization schedule, reducing the number of vaccine recommendations from 18 to 11, do not automatically create enforceable obligations for parents, schools or healthcare providers, but may spur litigation and other downstream effects on school policies and state guidelines, says Mehdi Sinaki at Michelman & Robinson.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.